Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations.
Up till now the role of simeprevir plasma concentrations has not been described in treated patients affected by chronic hepatitis C and with dermatological side-effects. In this study, we have evaluated a possible relationship between plasma levels and the onset of skin complaints for the first time. We report a clinical and pharmacokinetic analysis of 56 patients treated with simeprevir-based therapies. Simeprevir plasma concentrations were significantly related to dermatological side-effects at early time-points (P<0.001). In logistic regression, simeprevir concentrations at 1 week was the best predictive factor forskin symptoms (OR=1.901, 95%IC: 1.001-2.304; P=0.007). Simeprevir plasma measurements could be a useful tool in a real-life clinical setting for prevention of dermatological symptoms.